Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 19Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Non-Hodgkin 8Neoplasms 7Lymphoma 7Recurrence 5Lymphoma, B-Cell 5Multiple Myeloma 4Burkitt Lymphoma 4Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Prolymphocytic, B-Cell 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1

Interventions

enzalutamide 4darolutamide 2xentuzumab 1olaparib 1ipatasertib 1ibrutinib 1gallium 68 PSMA-11 1atezolizumab 1apalutamide 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Docetaxel 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms, Castration-Resistant × ibrutinib × Clear all
NCT06788509 2026-05-08

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡